• Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
  • Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
Home News & Views

News & Views

FILTER:
All ASX BD&AM BDAM Clinical Events News Prostate Cancer Awareness Month Scientific Publication Uncategorized

AUDIO LINK NOT ATTACHED – Telix Half-Year Results 2021 and Company Update Conference Call

Telix announces Half-Year Results 2021 and provides shareholder update
Read more

Telix Expands Prostate Cancer Activity with GenesisCare Collaboration

Telix releases details of two ancillary studies under the ProstACT program, including a Phase II study in collaboration with GenesisCare.
Read more

Telix H1 2021 Results and Company Update Conference Call

Telix to hold investor conference call to present H1 2021 financial results and Company update.
Read more

Activities Report and Appendix 4C for June 2021 Quarter

Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June 2021.
Read more

Telix Update on FDA New Drug Application Review for Illuccix®

Telix announces participation in a late-cycle meeting with the U.S. FDA regarding the ongoing review of the NDA for its prostate cancer imaging investigational product Illuccix®.
Read more

Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy

Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of Telix, and Alpha Therapy Solutions announce €990K (A$1.56M) ‘Eurostars-2’ research grant from the EUREKA Association.
Read more

Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging

Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate cancer imaging product Illuccix® and EZAG’s GalliaPharm® gallium-68 generator.
Read more

Telix Pharmaceuticals and Eckert & Ziegler Sign German Distribution Agreement for Prostate Cancer Imaging

Telix has entered an exclusive commercial distribution agreement with Eckert & Ziegler for Telix’s prostate cancer imaging product Illuccix® for the German market.
Read more

Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses

Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of Shareholders.
Read more

Telix and Monrol Expand Alliance to Include Lutetium Supply

Telix announces global clinical supply agreement with Monrol for the supply of no carrier added lutetium-177 for use in Telix’s MTR products.
Read more
Previous page 1 … 17 18 19 20 21 … 26 Next page
  • Our Company
  • Our Portfolio
  • Investor Center
  • News & Views
  • Careers
  • Contact Us
  • Telix Hotline
  • Legal Notices

Subscribe to our newsletter to stay in the loop

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.​
The Telix Pharmaceuticals, the Illuccix and Gozellix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.​
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.​

  • Privacy Policy
  • Terms of Use
  • Cookies Policy
  • Consumer Health Privacy Notice
  • Privacy Settings

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”